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Abstract
Background: Lymph node involvement in pancreatic adenocarcinoma is a key prognostic factor.
Therefore, extending the number of lymph node stations excised in pancreatoduodenectomy may be
beneficial to patients with pancreatic adenocarcinoma. This systematic review and meta-analysis
examines the outcomes of extended versus standard lymphadenectomy in the published literature.
Methods: A meta-analysis of randomized controlled trials (RCTs) comparing extended with standard
lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma
was performed. Perioperative outcomes were assessed as pooled odds ratios (ORs) and weighted
mean differences. Overall survival was analysed for patients with positive and negative lymph nodes.
Results were reported according to the PRISMA statement.
Results: Five RCTs were included, accounting for 724 patients. Extended lymphadenectomy was
associated with greater operative time [mean difference: 63 min, 95% confidence interval (CI) 29–96;
P < 0.001], increased need for blood transfusions (mean difference: 0.20, 95% CI 0.01–0.30;
P = 0.030) and greater postoperative morbidity (OR 1.5, 95% CI 1.25–2.00; P = 0.030), as well as with
prolonged diarrhoea after circumferential autonomic nerve dissection around major vessels (OR 12.2,
95% CI 5.3–28.5; P < 0.001). Median survival was similar across the groups in the whole cohort, as
well as in subgroups of patients with, respectively, positive and negative lymph nodes.
Conclusions: Extended lymphadenectomy has a harmful impact on patients undergoing oncological
pancreatoduodenectomy compared with standard lymphadenectomy.
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Introduction
Pancreatic adenocarcinoma is the fourth most common cause
of cancer-related death in high-income countries.1 Complete
surgical resection in combination with systemic chemotherapy
offers the only chance of potential cure for patients diagnosed
with pancreatic adenocarcinoma. Even with such an approach,
early recurrence and associated short survival are common out-
comes in many patients.
Lymph node involvement is a key prognostic factor in pan-
creatic adenocarcinoma.2 Although the American Joint Com-
mittee on Cancer (AJCC) staging system does not discriminate
among several categories of lymph node positivity,3 recent evi-
dence has shown that subtle but clinically meaningful sub-
groups of patients can be distinguished based on the number
of positive lymph nodes (PLNs), examined lymph nodes
(ELNs), and lymph node ratio [LNR (PLNs divided by
ELNs)].2 To potentially improve the clearance of infiltrated
lymph nodes, extended lymphadenectomy when performing
oncological pancreatoduodenectomy (PD) has been proposed
by some authors.4
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Previous studies5,6 have failed to demonstrate an impact of
extended lymphadenectomy on perioperative morbidity or sur-
vival. However, these systematic reviews are difficult to inter-
pret because they aggregate results gathered from both
retrospective and non-randomized studies. Recently, two a pri-
ori powered randomized controlled trials (RCTs) of extended
lymphadenectomy in PD have been published.7,8 The current
meta-analysis of RCTs compares extended (or radical) with
standard lymphadenectomy in patients undergoing PD for
pancreatic adenocarcinoma and looks at perioperative compli-
cations and longterm survival.
Materials and methods
Search strategy and study selection
A systematic review and meta-analysis was performed accord-
ing to the PRISMA (preferred reporting items for systematic
reviews and meta-analyses) statement.9 Search strategy, trial
selection, data extraction and analyses were undertaken accord-
ing to a predefined protocol, which was registered in the
PROSPERO database (CRD 42014013491). The Cochrane Cen-
tral Register of Controlled Trials, MEDLINE and EMBASE
were searched using combinations of terms including ‘pancre-
atoduodenectomy’, ‘pancreatic adenocarcinoma’, and ‘radical’
or ‘extended’ or ‘standard’ ‘lymphadenectomy’ (The exact
search strategy can be found in the Appendix S1, online). Only
published studies with an English-language abstract comparing
standard versus extended lymphadenectomy were included.
Duplicate entries were excluded. Search results were cross-ref-
erenced with previous meta-analyses and hand-searches of the
reference lists of retrieved articles were also performed to
ensure sensitivity in the identification of relevant RCTs. Two
authors (LAO and JM) performed the database searches. Arti-
cles were initially screened based on title and abstract. Poten-
tially relevant papers were explored after their full texts had
been obtained. To be included, RCTs were required to com-
pare the outcomes of extended lymphadenectomy with those
of usual care. It was anticipated that the extent of lymph node
excision in both the radical and standard procedures might
differ depending on the usual practice of surgeons in different
regions of the world. Thus inclusion was not restricted to trials
comparing excisions of exactly the same combinations of
lymph node stations. Instead, the analysis was planned to
include studies comparing a strategy of more aggressive lymph
node dissection with usual care, and to investigate clinical vari-
ability where required. To ensure comparison worthiness, trials
were included only if they reported the number of ELNs in
both groups. Quasi-randomized studies, secondary analyses of
preliminary results, and trials that did not provide survival
estimates beyond the early postoperative period were excluded.
Data collection and study quality assessment
Two reviewers (LAO and JM) extracted data on study charac-
teristics, baseline clinical variables and outcomes of interest.
When several publications nested in the same RCT were avail-
able, the most recent and complete estimates were extracted.
The quality of each study was assessed according to the Jadad
score.10 This score contains two items each for randomization
and double-blinding, and one item to evaluate the reporting of
cohort attrition. The maximum Jadad score is 5; studies scor-
ing ≥3 are considered of superior quality. Allocation conceal-
ment and sample size calculation were also evaluated.
Outcomes of interest
The current meta-analysis was designed to evaluate three types
of outcome: (i) outcomes pertaining to the surgical procedure
itself, including operative time and surgical bleeding (as
assessed by red blood cell units transfused); (ii) postoperative
outcomes, such as morbidity [including the occurrence of
overall complications, postoperative pancreatic fistula (POPF),
postoperative bleeding, early re-laparotomy, intra-abdominal
abscess, delayed gastric emptying (DGE), lymphoceles, bile
leaks, cholangitis, wound infections], length of hospital stay,
and diarrhoea beyond the early postoperative period, and (iii)
long term survival and recurrence patterns.
Data analysis
Dichotomous outcomes were pooled as odds ratio (OR) using
the Mantel–Haenszel model. For continuous outcomes, the
inverse variance method was used to calculate the weighted
mean difference (WMD). Heterogeneity was assessed using the
Q test and quantified using the I2 statistic. Models with ran-
dom effects were applied when heterogeneity was detected
(P-value for Q test: <0.100). Survival estimates in the
‘Extended’ and ‘Standard’ study arms were extracted from
published survival curves for follow-up from 6 months to
60 months in steps of 6 months using the R package Digitize
(R Foundation for Statistical Computing, Vienna, Austria).11
For this purpose, survival curves were digitalized with the
package ReadImage (R Foundation for Statistical Computing).
Survival estimates were combined as previously described.12
Effective numbers of at-risk patients were derived for intervals
of time (0–6 months, 6–12 months, 12–18 months,. . .,
52–60 months) from sample sizes13 and censored data on sur-
vival curves were reported (for four studies7,8,14,15) or extrapo-
lated as per Tierney et al.16 (for one study17). Combination of
survival estimates were conducted for all patients and for
patients with positive and negative lymph nodes, respectively.
Pooled survival estimates were reported with 95% confidence
intervals (95% CIs) and plotted as summary survival curves.
Hazard ratios (HRs) were estimated from extracted survival
probabilities by calculating relative logarithms of survival for
intervals of 6 months (until 60 months).18 Using multivariate
meta-analysis,19 relative logarithms of survival were combined
for each time interval in a single model accounting for random
effects (restricted maximum likelihood estimator). As recom-
mended,13 a variation of the effect over time was tested in
HPB 2015, 17, 565–572 ª 2015 International Hepato-Pancreato-Biliary Association
566 HPB
meta-regression analysis using the R package ‘metafor’
(R Foundation for Statistical Computing). Because the inter-
vention effect was approximately constant over time, a pooled
HR over the entire follow-up was determined. Pooled HRs in
patients with, respectively, positive and negative lymph nodes
were also compared. A leave-one-out sensitivity analysis was
conducted. Significance was accepted at the two-sided 5% level.
Analyses were performed using RevMan Version 5.2 (Nordic
Cochrane Centre, Copenhagen, Denmark). For some analyses,
the R packages ‘msurv’ and ‘mvmeta’ (R Foundation for Statis-
tical Computing) were used.
Results
Study selection
Database searches identified 422 studies (Fig. 1), out of which
eight published reports of RCTs were retained.7,8,14,15,17,20–22
One RCT gave rise to several publications reporting different
outcomes17,20–22 (preliminary results, longterm follow-up, qual-
ity of life assessment). Finally, five studies7,8,14,15,17 were
included (Table 1). In terms of methodological quality, the
studies included were well designed and all but one15 reported
power calculation. Randomization was performed intraopera-
tively in three studies.14,15,17 Allocation concealment was
described in two studies.7,8 Only the most recent RCT7
reported a double-blind design and two trials8,17 used single
blinding of the outcome assessors.
Two studies did not administer adjuvant therapy,8,15 two
routinely used 5-fluorouracil and external beam radia-
tion,14,17 and one administered various protocols of systemic
therapy.7
Surgical procedures
As expected, the number of ELNs was significantly higher in
the extended lymphadenectomy groups in all study cohorts,
with a pooled WMD of 14 lymph nodes (95% CI 10–19;
P < 0.001). However, there was some clinical variability in the
extent of lymph node clearance. Briefly, the main difference
referred to the increased clearance of para-aortic and coeliac
axis lymph nodes in the radical procedures, followed by lymph
nodes of the hepatoduodenal ligament (Fig. 2; Japanese classifi-
Records identified through 
database searching 
(n = 422)
Additional records identified 
through other sources 
(n = 0)
Records after duplicates removed 
(n = 292, 100%)
(n = 292, 100%)
Records screened Records excluded 
(n = 275, 94%)
Full-text articles assessed 
for eligibility 
(n = 17, 6%)
Full-text articles excluded 
(n = 12, 4%) 
[reviews (n = 2), 
randomized studies (n = 7), 
secondary analyses (n = 3)]
Studies included in 
qualitative synthesis 
(n = 5, 2%)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 5, 2%)
Figure 1 Results of the PRISMA-based protocol for the study inclusion and exclusion process
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cation23). Some studies performed circumferential nerve plexus
dissection around the superior mesenteric artery (SMA),8,14,15
the coeliac axis,14,15 and the hepatic artery.8,14 The remaining
studies restricted nerve dissection to a semi-circumferential
right lateral aspect. In Farnell et al.,14 pylorus preservation was
not allowed in either of the two study groups, whereas Riall
et al.17 considered distal gastrectomy as part of the radical pro-
cedure only. The remaining studies left the decision on
whether or not to perform pylorus-preserving PD to the dis-
cretion of the surgeon.
Perioperative outcomes
Compared with those submitted to standard lymphadenecto-
my, patients allocated to extended lymphadenectomy experi-
enced significantly prolonged operative time (WMD 63 min,
95% CI 29–96; P < 0.001, Q test P < 0.100, I2 = 79%, ran-
dom-effects model), and required marginally more transfusions
(WMD 0.20 units, 95% CI 0.01–0.30; P = 0.030, Q test
P = 0.690, fixed-effects model). Overall complications were sig-
nificantly more common in the extended lymphadenectomy
group (OR 1.5, 95% CI 1.1–2.0; P = 0.030, Q test P = 0.200,
fixed-effects model). However, occurrences of single morbidi-
ties did not differ statistically significantly between groups (all
Q tests, P > 0.100, fixed-effects model), including for POPF
(OR 1.6, 95% CI 0.9–2.7; P = 0.100), bile leaks (OR 3.1, 95%
CI 1.0–9.9; P = 0.050), lymphoceles (OR 5.2, 95% CI 0.9–30.4;
P = 0.070) and wound infections (OR 1.9, 95% CI 1.0–3.5;
P = 0.050). There was no evidence of any differences in occur-
rences of cholangitis (OR 1.3, 95% CI 0.3–4.8; P = 0.730),
DGE (OR 1.5, 95% CI 0.6–3.6; P = 0.400), postoperative
bleeding (OR 1.3, 95% CI 0.4–3.9; P = 0.620), re-laparotomy
(OR 1.1, 95% CI 0.4–3.0; P = 0.810), or length of hospital stay
(WMD 1 day, 95% CI 2 to +4; P = 0.580) (Figs S1 and S2,
online). In studies in which circumferential nerve plexus clear-
ance around the SMA was performed for radical resec-
tion,8,14,15 patients had markedly higher odds of experiencing
prolonged diarrhoea (OR 12.2, 95% CI 5.329.5; P < 0.001, Q
test P = 0.100). By contrast, pooled results of studies that
involved semi-circumferential nerve dissection showed diar-
rhoea to be equally common in the extended and standard
lymphadenectomy groups (OR 1.2, 95% CI 0.6–2.5;
P = 0.630).
Survival analyses
Pooled summary survival curves are shown in Fig. 3(a). Given
the between-study variability (I2 = 51.4% and 50.0%, respec-
tively), subgroup analyses of patients according to lymph node
status (positive and negative, respectively) were also carried
out (Fig. 3b and c). Briefly, survival estimates were similar
across groups, both in the whole population and within sub-
groups of patients with positive and negative lymph nodes.
To determine whether extended lymphadenectomy impacted
on survival, estimated HRs for patients with positive and nega-
tive lymph node in each individual study were assessed
(Fig. 4). Pooled HRs were not significant for any time interval
for patients with either positive or negative lymph nodes and
there was no evidence that the HR varied over time (patients
with positive and negative lymph node meta-regression
P = 0.184 and P = 0.904, respectively). Therefore, the results
were pooled over the entire follow-up, yielding pooled HRs
(extended versus standard lymphadenectomy) of 0.98 (95% CI
0.66–1.46; P = 0.913) and 1.06 (95% CI 0.69–1.64; P = 0.793)
for patients with positive and negative lymph nodes. As
another approach, the HRs of patients with positive and nega-
tive lymph nodes were compared in a meta-regression with
lymph node positivity as a predictor. Again, no statistically
significant difference (P = 0.860) was observed, suggesting that
extended lymphadenectomy is ineffective in both populations.
Finally, when data for both patients with positive and those
with negative lymph nodes were combined, the overall pooled
HR (extended versus standard lymphadenectomy) was 1.01
(95% CI 0.77–1.34; P = 0.923). In the leave-one-out sensitivity
Table 1 Characteristics of the included studies







Extended Standard Extended Standard Extended Standard
Pedrazzoli et al.15 41 40 Italy Multicentre 3 19.8  15.1 13.3  8.3 +/+/ //
Riall et al.17 148a 146a USA Monocentre 5 28.5  7.3 17.0  7.3 // //
Farnell et al.14 39 40 USA Monocentre 2 34  17 15  7 +/+/+ //
Nimura et al.8 50 51 Japan Multicentre 3 40.1  33.2 13.3  33.2 +//+ //
Jang et al.7 86 83 South
Korea
Multicentre 5 33.7  15.1 17.3  10.6 // //
a
For Riall et al., survival analyses were computed after the exclusion of patients with pathological diagnoses other than pancreatic adenocarci-
noma.
SD, standard deviation; SMA, superior mesenteric artery.
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analysis, this HR ranged from 0.93 (95% CI 0.72–1.21;
P = 0.595) when the study by Nimura et al.8 was removed to
1.10 (95% CI 0.84–1.42; P = 0.491) when the study by
Pedrazzoli et al.15 was removed. The findings were robust with
regard to all of the studies.
Finally, two studies7,8 provided detailed tables of recur-
rence patterns; there was no pooled difference in site of
recurrence (local, peritoneal, lymphatic, hepatic) in the
extended versus standard lymphadenectomy groups (data not
shown).
Discussion
This meta-analysis reveals that extended lymphadenectomy in
PD is associated with increases in operative time, requirements
for blood transfusions and incidence of overall complications.
With reference to the longterm prognosis, there is no evidence
of a benefit of extended lymphadenectomy. Thus, the available
evidence suggests that extended lymphadenectomy in PD is a
harmful intervention. These findings deserve further comment.
Although intuitively meaningful, extended lymphadenectomy
entails increased surgical manipulation, and local cancer cell
dissemination may be an unanticipated harmful event when
embarking on a radical retroperitoneal dissection. Although in
the present analysis, group allocation (extended versus stan-
dard lymphadenectomy) was not associated with site of recur-
rence, only two studies reported recurrence patterns (with an
increased rate of peritoneal recurrence after extended lympha-
denectomy in one study23) and thus this outcome may lack
statistical power. Tumour manipulation leads to free cancer
cell detection in lymphatic fluid and portal blood,24 and
although findings are not uniform,25 several studies have
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20.8%              6.50 [1.21, 11.79]     
28.0%            11.50 [9.84, 13.16]     
23.8%          16.40 [12.48, 20.32]     
18.9%          19.00 [12.87, 25.13]     
  8.5%          26.80 [13.85, 39.75]     
Total (95% CI)                      359                  358        100.0%            14.35 [9.86, 18.84]     
Heterogeneity: Tau2 = 18.02; chi2 = 19.09,df = 4 (P = 0.0008); I2 = 79%     
Test for overall effect: Z = 6.26 (P < 0.00001)     
Pedrazzoli et al. (1998)15       41                   40
Riall et al. (2005)17               148                  146
Jang et al. (2014)7                  86                      83
Farnell et al. (2005)14             34                   38




 IV, Random, 95% CI
Figure 2 Lymph nodes harvested during (a) standard and (b) extended lymphadenectomy. The colour code indicates numbers of studies
harvesting the relevant lymph node groups (Japanese classification). (c) Forest plot illustrating the number of resected lymph nodes
(random-effects model). The vertical line shows the null hypothesis; the surface areas of the blue rectangles indicate the weight of
individual studies in the pooled analysis and the black diamond depicts the pooled effect size. 95% CI, 95% confidence interval.
(Adapted from the Japanese Gastric Cancer Association,23 with permission)
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documented a harmful impact of circulating cancer cells on
the survival of pancreatic cancer patients.26,27 In this regard,
innovative strategies, such as the ‘no-touch’ PD, have been
designed to minimize the local spread of cancer cells.28,29 By
hanging up the pancreatic head using a tape placed along the
posterior aspect of the Gerota fascia, ‘no-touch’ pancreatec-
tomy allows the surgeon to resect the duodenopancreatic bloc
without grasping and squeezing the tumour, thus theoretically
minimizing cancer cell shedding. A pilot retrospective analysis
reported encouraging results24 and a recent small RCT
(n = 12) reported by Gall et al. demonstrated an increase in
the number of circulating cancer cells in the portal blood in
83% of patients following standard resection versus 0% follow-
ing a no-touch approach (P = 0.003).30 Survival was not
significantly longer in patients allocated to the no-touch tech-
nique (P = 0.330).30 Therefore, although such an approach is
conceptually appealing, its clinical effectiveness remains to be
formally determined.
Given that most of the trials reported a priori sample size
calculations based on longterm survival, that the present sur-
vival meta-analysis pools data from all five studies, and that
the estimated HRs were not only non-significant but also very
close to null (extended versus standard lymphadenectomy: HR
1.01, 95% CI 0.77–1.34; P = 0.923), it appears that the lack of
association between the extent of lymphadenectomy and sur-
vival truly reflects a lack of efficacy of the intervention, rather
than residual type II error. However, these observations should


































































Figure 3 Summary survival curves with 95% confidence bands (dashed lines) represented by study groups (black lines for extended









































Figure 4 Pooled estimates of hazard ratios (HRs) for each interval of time (black squares) and for the overall follow-up (grey horizontal
line) in (a) lymph node-positive and (b) lymph node-negative patients. Vertical black lines represent 95% confidence intervals around the
pooled HRs in each interval of time and the grey dashed horizontal line represents the 95% interval around the HR pooled over the
entire follow-up. Circles represent estimated HRs extracted from studies
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included used a non-inferiority design. Interestingly, the cur-
rent findings reproduce the evidence surrounding the role of
radical lymphadenectomy in gastric cancer surgery. In a recent
meta-analysis, extended lymphadenectomy for proven gastric
adenocarcinoma was associated with significantly higher rates
of anastomotic leak, overall complications and reoperations,
and with 5-year survival similar to that subsequent to the stan-
dard approach.31
Diarrhoea, as assessed up to 4 months after surgery, was
markedly more common (OR 12.24, 95% CI 5.26–28.47) in
patients in whom nerve tissue surrounding the SMA was
cleared circumferentially. By contrast, in studies in which only
the right lateral aspect of the nerve plexus was dissected, no
impact on intestinal transit was observed. Of note, in the trial
by Jang et al.,7 two patients (one of whom subsequently died)
in the extended lymphadenectomy group developed SMA
pseudoaneurysm after nerve dissection. Thus, nerve plexus dis-
section not only alters intestinal transit, but also seems to fos-
ter the occurrence of vascular complications, which are a
common cause of severe morbidity after pancreatectomy.
The strengths of this meta-analysis include, firstly, its power,
which allowed the uncovering of increased postoperative mor-
bidity in the extended lymphadenectomy group, and, secondly,
its ability to reconstitute pooled survival curves, as well as to
estimate aggregate HRs, which did not indicate that overall
survival was affected by the type of lymphadenectomy. How-
ever, there are some limitations to the present study. Firstly,
given the large number of lymph node stations populating the
upper abdominal cavity, some clinical variability is unavoidable
when data from trials completed on various continents are
pooled. In this respect, clinical variability has been thoroughly
inspected (Fig. 2) and it appears that the by far most common
differences between standard and extended lymphadenectomy
concern para-aortic and coeliac lymph nodes, as well as nerve
plexus dissection around the SMA and coeliac axis. Secondly,
although they are informative, subgroup analyses of outcomes
in patients with, respectively, positive and negative lymph node
patients should be interpreted with caution because randomi-
zation allows a random distribution of confounders in the
whole study population, but does not guarantee the compara-
bility of specific subgroups (e.g. patients with, respectively,
positive and negative lymph nodes).
In conclusion, this meta-analysis does not support any
impact of extended lymphadenectomy on longterm oncological
outcomes after PD, but rather demonstrates that extended lym-
phadenectomy jeopardizes the postoperative course of patients
undergoing this procedure. Based on these results, extended
lymphadenectomy should not be applied routinely in patients
with pancreas head adenocarcinoma requiring PD. However,
in an era of patient-centred medicine, some components of
extended PD (e.g. nerve dissection) may still be regarded as
beneficial in some patients in whom the tumour is located near
the SMA in order to achieve negative-margin resection.
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Supporting information
Additional Supporting Information may be found in the online version of this
article:
Figure S1. Results of pooled analyses of perioperative outcomes: (a) opera-
tive time; (b) units of red blood cells transfused; (c) overall complications;
(d) postoperative pancreatic fistula (POPF); (e) bile leaks, and (f) lymphoce-
les. Point estimates are shown with 95% confidence intervals. The vertical
line shows the null hypothesis. The surface areas of the blue rectangles
indicate the weight of individual studies in the pooled analysis.
Figure S2. Results of pooled analyses of perioperative outcomes: (a)
wound complications; (b) postoperative intra-abdominal bleeding; (c) re-lap-
arotomy; (d) delayed gastric emptying; (e) cholangitis, and (f) length of hos-
pital stay. Point estimates are shown with 95% confidence intervals. The
vertical line shows the null hypothesis. The surface areas of the blue rectan-
gles indicate the weight of individual studies in the pooled analysis.
Appendix S1. Search strategy run in MEDLINE.
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